Clinical Trial: Seroprevalence of Chikungunya at the End of the First Chikungunya Outbreak in the French Antilles Within a Sample of Patients Treated for a HIV Infection

Study Status: Completed
Recruit Status: Completed
Study Type: Observational

Official Title: Seroprevalence of Chikungunya at the End of the First Chikungunya Outbreak in the French Antilles Within a Sample of Patients Treated for a HI

Brief Summary:

Late 2013, the first indigenous cases of chikungunya have been observed in the French Antilles. At the end of May 2014, almost all of the islands of the Caribbean were affected by the outbreak.

During the large epidemic which affected the Island of La Réunion in 2005/2006, the attack rate was 38%. The most active period was three months.

In this context, knowledge of the attack rate and the epidemic in the Caribbean is an important issue for outbreak management and modeling work.

As the chikungunya virus had never circulated in the Caribbean, determining the seroconversion rate can be achieved by realizing a seroprevalence survey among the general population at the end of the outbreak. Another simple method is to estimate the rate in a cohort of patients followed regularly and whose habitat is distributed throughout the territory studied.

The follow up of patients infected by the human immunodeficiency virus (HIV) in the French West Indies is almost exclusively performed in hospitals in department of Infectious and Tropical Diseases.The high prevalence of HIV and homogeneous distribution of infected patients on all of our territories, allow to hypothesize that the risk of transmission of arboviruses by exposure to mosquito bites is comparable to the general population. This patient cohort is well suited to study the emergence of Chikungunya in the French West Indie .

Primary objective :

To estimate the cumulative incidence at the end of the first Chikungunya outbreak in the French West Indies by estimating the prevalence of specific antibodies of chikungunya virus in a sample (randomly constituted) from patients infected

Detailed Summary:
Sponsor: University Hospital Center of Martinique

Current Primary Outcome: Presence or not of chikungunya virus-specific immunoglobulin G antibodies (Elisa test) [ Time Frame: 1 day ]

Presence or not of chikungunya virus-specific immunoglobulin G antibodies


Original Primary Outcome: Same as current

Current Secondary Outcome: Change From Baseline in Pain [ Time Frame: 6 , 12 , 18 months after the first symptoms of chikungunya virus infection ]

Score range from 0 (No pain) to 10 (worst possible pain)


Original Secondary Outcome: Same as current

Information By: University Hospital Center of Martinique

Dates:
Date Received: September 14, 2015
Date Started: February 2015
Date Completion:
Last Updated: July 25, 2016
Last Verified: July 2016